Drugs / RDX013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04780841 | Jan → Dec 2021 | — | Ardelyx | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-07-14 | Ardelyx | Results Ardelyx to Provide Updates on Research and Development Programs at Today's Inaugural R&D Day in New York City ardelyx.com ↗
The Company will present proof-of-concept data demonstrating potassium secretion in a pre-clinical model. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-07-14 | Ardelyx | Ardelyx to Provide Updates on Research and Development Programs at Today's Inaugural R&D Day in New York City ardelyx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RDX013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04780841 ↗ |
| Route | Oral | “RDX013 low dose oral dosage, twice daily” NCT04780841 ↗ |